Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medical solutions company Medical Developments International (MVP) is now allowed to sell its pain relief medication, Penthrox, in Hungary
  • Penthrox can be used for emergency relief of moderate to severe pain in adult patients with trauma and associated pain
  • While MVP’s European decentralised procedure and national phase is now complete, the company said it is yet to achieve government reimbursement
  • Once Medical Developments receives government reimbursement for Penthrox, the product will be free for patients to purchase
  • This announcement follows approvals in Bosnia and Herzegovina, which were received earlier this month
  • Medical Developments is up 4.1 per cent on the market today, trading for $8.13 per share

Medical solutions company Medical Developments International (MVP) is now allowed to sell its pain relief medication, Penthrox, in Hungary.

Penthrox is a fast non-opioid pain relief medication for patients with trauma and those requiring medication to relieve pain for surgical procedures.

In Hungary, Penthrox can now be used for emergency relief of moderate to severe pain in adult patients with trauma and associated pain.

Whilst MVP’s European decentralised procedure and national phase is now complete, the company said it is yet to achieve government reimbursement. However, sales can still be made to the private market.

This announcement follows approvals in Bosnia and Herzegovina, which were received earlier this month. Medical Developments says it is also currently waiting for approvals in Greece and Malta.

Medical Developments is up 4.10 per cent on the market today, trading for $8.13 per share at 1:30 pm AEST.

MVP by the numbers
More From The Market Herald
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.